EP Wire - Practice of use of NOAC therapies in Europe

Q1 Is your institution :

Answered: 45 Skipped: 0



Answer Choices	Responses	
A university hospital	**66.67%**	30
A private hospital	**22.22%**	10
Other type of hospital	**11.11%**	5
Total		45

EP Wire - Practice of use of NOAC therapies in Europe

Q3 Would you be comfortable if we acknowledge your centre in the Europace Journal and on the Website ?

Answered: 45 Skipped: 0



Answer Choices	Responses	
Yes	**97.78%**	44
No	**2.22%**	1
Total		45

EP Wire - Practice of use of NOAC therapies in Europe

Q4 Type of cardiology clinical service :

Answered: 44 Skipped: 1



Answer Choices	Responses	
General hospital, non-electrophysiology	**6.82%**	3
Electrophysiology centre	**90.91%**	40
Other	**2.27%**	1
Total		**44**

EP Wire - Practice of use of NOAC therapies in Europe

Q5 Does your hospital/department have a dedicated atrial fibrillation and/or arrhythmia clinic or section?

Answered: 44 Skipped: 1



Answer Choices	Responses	
Yes	**75%**	33
No	**25%**	11
Total		44

#	Other (please specify)	Date
1	EP is part of the cardiology centre	5/21/2013 11:05 PM

EP Wire - Practice of use of NOAC therapies in Europe

Q6 Do you have cardiac surgery at your institution?

Answered: 44 Skipped: 1



Answer Choices	Responses	
Yes	**81.82%**	36
No	**18.18%**	8
Total		**44**

Q7 Number of ICD implantations (Including CRT-Ds) at your institution (including box changes) last calender year :

Answered: 44 Skipped: 1



Answer Choices	Responses	
1 - 99	**45.45%**	20
100 - 199	**36.36%**	16
200 - 399	**4.55%**	2
400 or more	**13.64%**	6
None	**0%**	0
Total		44

#	What percentage of ICD Implants receives CRT-D ?
1	25
2	15
3	26%
4	30
5	95%
6	25
7	40
8	50
9	50
10	25
11	25%
12	40
13	33
14	50
15	66%
16	33
17	34
18	10%
19	50%
20	25%
21	80
22	60%
23	40%
24	33

Q8 Number of pacemaker implantations (sum of new implants and replacements) at your institution last calendar year :

Answered: 44 Skipped: 1



Answer Choices	Responses	
1 - 99	**15.91%**	7
100 -199	**25%**	11
200 - 399	**40.91%**	18
400 or more	**18.18%**	8
None	**0%**	0
Total		44

#	What percentage of your Pacemaker implants receives CRT-P ?
1	25
2	15%
3	2-3
4	10
5	15
6	10
7	5%
8	2
9	25
10	10
11	5%
12	18
13	5
14	5%
15	40%
16	5%
17	20
18	20 %
19	7%
20	10%
21	20

Q9 Total number of Catheter ablations (all types of arrhythmia) at your institution last calender year :

Answered: 44 Skipped: 1



Answer Choices	Responses	
1 - 99	**25%**	11
100 -199	**20.45%**	9
200 - 399	**22.73%**	10
400 or more	**27.27%**	12
None	**4.55%**	2
Total		**44**

#	What percentage of ablation procedures are left atrial AF ablations
1	0
2	27%
3	0
4	0
5	5
6	0
7	15
8	10%
9	0
10	3
11	25
12	0%
13	50
14	55
15	50
16	70%
17	50%
18	0%
19	40
20	60%
21	30%
22	50

Q10 For AF patients taking Vitamin K Antagonists [VKAs], who is the main person/clinic that monitors their anticoagulation, in the majority of cases?

Answered: 44 Skipped: 1



Answer Choices	Responses	
Dedicated anticoagulant clinic	**31.82%**	14
Cardiologist	**34.09%**	15
General internal medicine clinic	**0%**	0
General practitioner	**36.36%**	16
Patient self-monitoring	**2.27%**	1
No specific anticoagulation monitoring services in place	**4.55%**	2
Total Respondents: 44		

EP Wire - Practice of use of NOAC therapies in Europe

Q11 For AF patients takingVKAs, which is the main type of VKA used ?

Answered: 44 Skipped: 1



Answer Choices	Responses	
Warfarin	**43.18%**	19
Acenocoumarol	**36.36%**	16
Phenindione	**0%**	0
Phencoumarol	**13.64%**	6
Other ...	**6.82%**	3
Total		44

Q12 Which scoring system do you use to assess stroke risk in your everyday practice

Answered: 44 Skipped: 1



Answer Choices	Responses	
CHADS2	**6.82%**	3
CHA2DS2-VASc	**93.18%**	41
Van Walraven	**0%**	0
Framingham	**0%**	0
Qstroke	**0%**	0
Clinical judgement	**0%**	0
No stroke risk assessment made	**0%**	0
Total		44

Q13 Which scoring system do you use to assess bleeding risk in your everyday practice

Answered: 44 Skipped: 1



Answer Choices	Responses	
HEMORRH2AGES	2.27%	1
HAS-BLED	86.36%	38
ATRIA	0%	0
Shireman	0%	0
ORBI	0%	0
Clinical judgement	6.82%	3
No bleeding assessment made	4.55%	2
Total		44

EP Wire - Practice of use of NOAC therapies in Europe

Q14 Which novel oral anticoagulant [NOAC] is available for you to prescribe in your country ?

Answered: 32 Skipped: 13



Answer Choices	Responses	
Dabigatran	**90.63%**	29
Rivaroxaban	**78.13%**	25
Apixaban	**40.63%**	13
None available	**6.25%**	2
Do not prescribe	**3.13%**	1
Total Respondents: 32		

#	For those NOT prescribing please answer next Q, others might skip.	Date
1	Only private patients without reimbursement	6/4/2013 1:19 PM

EP Wire - Practice of use of NOAC therapies in Europe

Q15 If you do not prescribe NOACs, why not?

Answered: 13 Skipped: 32



Answer Choices	Responses	
Don't know enough about it	**0%**	0
Someone else does it for me	**15.38%**	2
Too expensive	**38.46%**	5
Not available	**46.15%**	6
Total Respondents: 13		

EP Wire - Practice of use of NOAC therapies in Europe

Q16 In patients starting VKAs, do you have a counselling session with information on do's and don'ts?

Answered: 32 Skipped: 13



Answer Choices	Responses	
Yes	**90.63%**	29
No	**9.38%**	3
Total		32

Q17 For your AF patients in the following categories, what average percentage are given VKA, NOAC, aspirin, aspirin-clopidogrel or nothing?




NOACs
Newly diagnosed new onset AF i...
Established patients ie, attending...
Paroxysmal AF patients, newly...
Paroxysmal AF patients, establishe...
Patients with AF undergoing cardioversion
Patients for ablation
Patients undergoing device...
Patients with AF presenting with an ac...
Patients with AF presenting with an ac...
Patients with AF requiring a...
0%
20%
40%
60%
80%
100%
1-9
10-19
20-29
30-49
50+
0


Aspirin
Newly diagnosed new onset AF i...
Established patients ie, attending...
Paroxysmal AF patients, newly...
Paroxysmal AF patients, establishe...
Patients with AF undergoing cardioversion
Patients for ablation
Patients undergoing device...
Patients with AF presenting with an ac...
Patients with AF presenting with an ac...
Patients with AF requiring a...
0%
20%
40%
60%
80%
100%
1-9
10-19
20-29
30-49
50+
0


Aspirin-clopidogrel
Newly diagnosed new onset AF i...
Established patients ie, attending...
Paroxysmal AF patients, newly...
Paroxysmal AF patients, establishe...
Patients with AF undergoing cardioversion
Patients for ablation
Patients undergoing device...
Patients with AF presenting with an ac...
Patients with AF presenting with an ac...
Patients with AF requiring a...
0%
20%
40%
60%
80%
100%
1-9
10-19
20-29
30-49
50+
0


Other type of antithrombotic drug eg. Dipyridamole, trifusal
Newly diagnosed new onset AF i...
Established patients ie, attending...
Paroxysmal AF patients, newly...
Paroxysmal AF patients, establishe...
Patients with AF undergoing cardioversion
Patients for ablation
Patients undergoing device...
Patients with AF presenting with an ac...
Patients with AF presenting with an ac...
Patients with AF requiring a...
0%
20%
40%
60%
80%
100%
1-9
10-19
20-29
30-49
50+
0


No antithrombotic drugs
Newly diagnosed new onset AF i...
Established patients ie, attending...
Paroxysmal AF patients, newly...
Paroxysmal AF patients, establishe...
Patients with AF undergoing cardioversion
Patients for ablation
Patients undergoing device...
Patients with AF presenting with an ac...
Patients with AF presenting with an ac...
Patients with AF requiring a...
0%
20%
40%
60%
80%
100%
1-9
10-19
20-29
30-49
50+
0

VKA							
	0	1undefined9	10undefined19	20undefined29	30undefined49	50+	Total
Newly diagnosed new onset AF ie first referral to you for management	3.23% 1	3.23% 1	3.23% 1	12.90% 4	29.03% 9	48.39% 15	31
Established patients ie, attending your clinic already for >1 year	0% 0	0% 0	3.13% 1	0% 0	12.50% 4	84.38% 27	32
Paroxysmal AF patients, newly diagnosed	3.13% 1	6.25% 2	6.25% 2	21.88% 7	15.63% 5	46.88% 15	32
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	0% 0	3.13% 1	0% 0	3.13% 1	21.88% 7	71.88% 23	32
Patients with AF undergoing cardioversion	3.13% 1	3.13% 1	0% 0	3.13% 1	3.13% 1	87.50% 28	32
Patients for ablation	6.67% 2	6.67% 2	0% 0	0% 0	13.33% 4	73.33% 22	30
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	3.13% 1	6.25% 2	3.13% 1	0% 0	3.13% 1	84.38% 27	32
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	12.50% 4	12.50% 4	0% 0	18.75% 6	12.50% 4	43.75% 14	32
Patients with AF presenting with an acute stroke (drugs on admission)	16.67% 5	6.67% 2	23.33% 7	3.33% 1	10% 3	40% 12	30
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	12.50% 4	9.38% 3	9.38% 3	6.25% 2	12.50% 4	50% 16	32

Aspirin							
	1undefined9	10undefined19	20undefined29	30undefined49	50+	0	Total
Newly diagnosed new onset AF ie first referral to you for management	34.48% 10	20.69% 6	3.45% 1	10.34% 3	6.90% 2	24.14% 7	29
Established patients ie, attending your clinic already for >1 year	46.67% 14	13.33% 4	6.67% 2	6.67% 2	6.67% 2	20% 6	30
Paroxysmal AF patients, newly diagnosed	40% 12	10% 3	10% 3	3.33% 1	10% 3	26.67% 8	30
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	43.33% 13	16.67% 5	6.67% 2	3.33% 1	6.67% 2	23.33% 7	30
Patients with AF undergoing cardioversion	32.14% 9	7.14% 2	0% 0	0% 0	0% 0	60.71% 17	28
Patients for ablation	25.93% 7	3.70% 1	7.41% 2	7.41% 2	0% 0	55.56% 15	27
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	42.86% 12	10.71% 3	0% 0	7.14% 2	3.57% 1	35.71% 10	28
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	26.67% 8	16.67% 5	13.33% 4	0% 0	30% 9	13.33% 4	30
Patients with AF presenting with an acute stroke (drugs on admission)	32.14% 9	14.29% 4	14.29% 4	3.57% 1	3.57% 1	32.14% 9	28
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	26.67% 8	16.67% 5	10% 3	6.67% 2	16.67% 5	23.33% 7	30

NOACs							
	1undefined9	10undefined19	20undefined29	30undefined49	50+	0	Total
Newly diagnosed new onset AF ie first referral to you for management	22.58% 7	19.35% 6	6.45% 2	9.68% 3	16.13% 5	25.81% 8	31
Established patients ie, attending your clinic already for >1 year	41.94% 13	19.35% 6	9.68% 3	9.68% 3	9.68% 3	9.68% 3	31
Paroxysmal AF patients, newly diagnosed	32.26% 10	22.58% 7	6.45% 2	9.68% 3	16.13% 5	12.90% 4	31
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	40% 12	20% 6	3.33% 1	10% 3	16.67% 5	10% 3	30
Patients with AF undergoing cardioversion	35.48% 11	16.13% 5	22.58% 7	12.90% 4	6.45% 2	6.45% 2	31
Patients for ablation	41.38% 12	0% 0	13.79% 4	10.34% 3	3.45% 1	31.03% 9	29
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	48.39% 15	9.68% 3	6.45% 2	6.45% 2	9.68% 3	19.35% 6	31
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	30% 9	16.67% 5	3.33% 1	6.67% 2	0% 0	43.33% 13	30
Patients with AF presenting with an acute stroke (drugs on admission)	39.29% 11	7.14% 2	7.14% 2	3.57% 1	7.14% 2	35.71% 10	28
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	43.33% 13	10% 3	6.67% 2	3.33% 1	0% 0	36.67% 11	30

Aspirin-clopidogrel							
	1undefined9	10undefined19	20undefined29	30undefined49	50+	0	Total
Newly diagnosed new onset AF ie first referral to you for management	32.26% 10	3.23% 1	0% 0	0% 0	0% 0	64.52% 20	31
Established patients ie, attending your clinic already for >1 year	32.14% 9	3.57% 1	0% 0	0% 0	3.57% 1	60.71% 17	28
Paroxysmal AF patients, newly diagnosed	30% 9	10% 3	0% 0	0% 0	0% 0	60% 18	30
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	37.93% 11	0% 0	0% 0	0% 0	3.45% 1	58.62% 17	29
Patients with AF undergoing cardioversion	24.14% 7	0% 0	0% 0	3.45% 1	0% 0	72.41% 21	29
Patients for ablation	29.63% 8	0% 0	0% 0	0% 0	0% 0	70.37% 19	27
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	35.71% 10	0% 0	3.57% 1	7.14% 2	0% 0	53.57% 15	28
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	33.33% 10	10% 3	0% 0	3.33% 1	26.67% 8	26.67% 8	30
Patients with AF presenting with an acute stroke (drugs on admission)	33.33% 9	11.11% 3	7.41% 2	0% 0	0% 0	48.15% 13	27
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	23.33% 7	3.33% 1	6.67% 2	10% 3	36.67% 11	20% 6	30

Other type of antithrombotic drug eg. Dipyridamole, trifusal							
	1undefined9	10undefined19	20undefined29	30undefined49	50+	0	Total
Newly diagnosed new onset AF ie first referral to you for management	6.67% 2	3.33% 1	0% 0	3.33% 1	0% 0	86.67% 26	30
Established patients ie, attending your clinic already for >1 year	13.79% 4	0% 0	0% 0	0% 0	3.45% 1	82.76% 24	29
Paroxysmal AF patients, newly diagnosed	13.33% 4	0% 0	0% 0	0% 0	0% 0	86.67% 26	30
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	10.34% 3	0% 0	0% 0	0% 0	3.45% 1	86.21% 25	29
Patients with AF undergoing cardioversion	10.71% 3	0% 0	0% 0	0% 0	0% 0	89.29% 25	28
Patients for ablation	14.81% 4	0% 0	0% 0	0% 0	0% 0	85.19% 23	27
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	10.71% 3	3.57% 1	0% 0	0% 0	0% 0	85.71% 24	28
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	13.79% 4	0% 0	0% 0	0% 0	0% 0	86.21% 25	29
Patients with AF presenting with an acute stroke (drugs on admission)	18.52% 5	0% 0	0% 0	0% 0	0% 0	81.48% 22	27
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	10% 3	0% 0	0% 0	0% 0	0% 0	90% 27	30

No antithrombotic drugs							
	1undefined9	10undefined19	20undefined29	30undefined49	50+	0	Total
Newly diagnosed new onset AF ie first referral to you for management	35.48% 11	19.35% 6	9.68% 3	3.23% 1	0% 0	32.26% 10	31
Established patients ie, attending your clinic already for >1 year	41.38% 12	3.45% 1	3.45% 1	0% 0	3.45% 1	48.28% 14	29
Paroxysmal AF patients, newly diagnosed	36.67% 11	10% 3	6.67% 2	0% 0	3.33% 1	43.33% 13	30
Paroxysmal AF patients, established ie, attending your clinic already for >1 year	37.93% 11	13.79% 4	0% 0	0% 0	3.45% 1	44.83% 13	29
Patients with AF undergoing cardioversion	17.24% 5	0% 0	0% 0	0% 0	0% 0	82.76% 24	29
Patients for ablation	18.52% 5	3.70% 1	0% 0	0% 0	0% 0	77.78% 21	27
Patients undergoing device (pacemaker, defibrillator) implantation (who also have AF)	32.14% 9	3.57% 1	0% 0	3.57% 1	0% 0	60.71% 17	28
Patients with AF presenting with an acute coronary syndrome (drugs on admission)	27.59% 8	3.45% 1	0% 0	0% 0	0% 0	68.97% 20	29
Patients with AF presenting with an acute stroke (drugs on admission)	14.29% 4	10.71% 3	3.57% 1	7.14% 2	3.57% 1	60.71% 17	28
Patients with AF requiring a percutaneous coronary intervention/stenting (drugs on admission)	23.33% 7	3.33% 1	0% 0	3.33% 1	0% 0	70% 21	30

Q18 In your AF patients who are taking a NOAC, what average percentage are given dabigatran, rivaroxaban or apixaban

Answered: 32 Skipped: 13



EP Wire - Practice of use of NOAC therapies in Europe



EP Wire - Practice of use of NOAC therapies in Europe



EP Wire - Practice of use of NOAC therapies in Europe




EP Wire - Practice of use of NOAC therapies in Europe
Apixaban 2.5mg bid
Overall use
Elderly patients, age >80
Patients with moderate renal...
Patients with prior coronary...
Patients on verapamil
Patients undergoing cardioversion
0%
20%
40%
60%
80%
100%
0
1-9
10-19
20-29
30-39
40-49
50+

EP Wire - Practice of use of NOAC therapies in Europe



Dabigatran 150mg bid								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	16.13% 5	9.68% 3	6.45% 2	12.90% 4	12.90% 4	16.13% 5	25.81% 8	31
Elderly patients, age >80	63.33% 19	20% 6	6.67% 2	0% 0	6.67% 2	3.33% 1	0% 0	30
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	86.67% 26	3.33% 1	3.33% 1	3.33% 1	0% 0	0% 0	3.33% 1	30
Patients with prior coronary artery disease (eg MI, stent etc)	46.67% 14	10% 3	6.67% 2	6.67% 2	16.67% 5	10% 3	3.33% 1	30
Patients on verapamil	70% 21	16.67% 5	6.67% 2	3.33% 1	3.33% 1	0% 0	0% 0	30
Patients undergoing cardioversion	20% 6	10% 3	6.67% 2	3.33% 1	13.33% 4	6.67% 2	40% 12	30

Dabigatran 110mg bid								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	9.68% 3	25.81% 8	19.35% 6	19.35% 6	6.45% 2	6.45% 2	12.90% 4	31
Elderly patients, age >80	16.67% 5	20% 6	6.67% 2	6.67% 2	6.67% 2	13.33% 4	30% 9	30
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	30% 9	16.67% 5	10% 3	6.67% 2	3.33% 1	3.33% 1	30% 9	30
Patients with prior coronary artery disease (eg MI, stent etc)	30% 9	20% 6	23.33% 7	10% 3	3.33% 1	0% 0	13.33% 4	30
Patients on verapamil	43.33% 13	23.33% 7	23.33% 7	0% 0	0% 0	3.33% 1	6.67% 2	30
Patients undergoing cardioversion	20% 6	23.33% 7	23.33% 7	10% 3	0% 0	13.33% 4	10% 3	30

Rivaroxaban 20mg od								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	38.71% 12	12.90% 4	6.45% 2	22.58% 7	3.23% 1	3.23% 1	12.90% 4	31
Elderly patients, age >80	65.52% 19	10.34% 3	6.90% 2	6.90% 2	10.34% 3	0% 0	0% 0	29
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	75.86% 22	10.34% 3	0% 0	6.90% 2	6.90% 2	0% 0	0% 0	29
Patients with prior coronary artery disease (eg MI, stent etc)	46.43% 13	14.29% 4	7.14% 2	7.14% 2	10.71% 3	3.57% 1	10.71% 3	28
Patients on verapamil	57.14% 16	7.14% 2	0% 0	10.71% 3	7.14% 2	0% 0	17.86% 5	28
Patients undergoing cardioversion	57.14% 16	3.57% 1	10.71% 3	7.14% 2	10.71% 3	0% 0	10.71% 3	28
Rivaroxaban 15mg od								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	43.33% 13	36.67% 11	16.67% 5	3.33% 1	0% 0	0% 0	0% 0	30
Elderly patients, age >80	37.93% 11	10.34% 3	10.34% 3	17.24% 5	6.90% 2	6.90% 2	10.34% 3	29
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	37.93% 11	13.79% 4	10.34% 3	13.79% 4	6.90% 2	0% 0	17.24% 5	29
Patients with prior coronary artery disease (eg MI, stent etc)	46.43% 13	25% 7	10.71% 3	7.14% 2	3.57% 1	0% 0	7.14% 2	28
Patients on verapamil	46.43% 13	17.86% 5	10.71% 3	14.29% 4	0% 0	0% 0	10.71% 3	28
Patients undergoing cardioversion	60.71% 17	25% 7	14.29% 4	0% 0	0% 0	0% 0	0% 0	28

Apixaban 5mg bid								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	81.25% 26	9.38% 3	6.25% 2	0% 0	0% 0	3.13% 1	0% 0	32
Elderly patients, age >80	89.66% 26	10.34% 3	0% 0	0% 0	0% 0	0% 0	0% 0	29
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	89.29% 25	3.57% 1	3.57% 1	3.57% 1	0% 0	0% 0	0% 0	28
Patients with prior coronary artery disease (eg MI, stent etc)	78.57% 22	14.29% 4	0% 0	0% 0	0% 0	3.57% 1	3.57% 1	28
Patients on verapamil	85.19% 23	3.70% 1	7.41% 2	0% 0	0% 0	3.70% 1	0% 0	27
Patients undergoing cardioversion	82.14% 23	14.29% 4	3.57% 1	0% 0	0% 0	0% 0	0% 0	28

Apixaban 2.5mg bid								
	0	1undefined9	10undefined19	20undefined29	30undefined39	40undefined49	50+	Total
Overall use	84.38% 27	12.50% 4	3.13% 1	0% 0	0% 0	0% 0	0% 0	32
Elderly patients, age >80	82.76% 24	10.34% 3	3.45% 1	0% 0	0% 0	3.45% 1	0% 0	29
Patients with moderate renal impairment egcreatinine clearance 30-49ml/min	82.14% 23	7.14% 2	7.14% 2	0% 0	0% 0	3.57% 1	0% 0	28
Patients with prior coronary artery disease (eg MI, stent etc)	82.14% 23	14.29% 4	3.57% 1	0% 0	0% 0	0% 0	0% 0	28
Patients on verapamil	85.19% 23	3.70% 1	3.70% 1	0% 0	3.70% 1	3.70% 1	0% 0	27
Patients undergoing cardioversion	85.71% 24	14.29% 4	0% 0	0% 0	0% 0	0% 0	0% 0	28

EP Wire - Practice of use of NOAC therapies in Europe

Q19 In patients undergoing elective cardioversion, would you prefer to use

Answered: 32 Skipped: 13



Answer Choices	Responses	
NOAC	**21.88%**	7
VKA	**46.88%**	15
No preference	**31.25%**	10
Total		32

EP Wire - Practice of use of NOAC therapies in Europe

Q20 In patients on a NOAC undergoing cardioversion, do you ask patients to sign an agreement or do you use a "dosage box or some kind of reminders" to be compliant with their drugs

Answered: 32 Skipped: 13



Answer Choices	Responses	
Yes	25%	8
No	75%	24
Total Respondents: 32		

EP Wire - Practice of use of NOAC therapies in Europe

Q21 In AF patients on a NOAC undergoing ablation, how do you manage?

Answered: 32 Skipped: 13



Answer Choices	Responses	
Continue NOAC uninterrupted	**12.50%**	4
Stop NOAC 1-2 days before, bridge with heparin and restart NOAC after haemostasis	**40.63%**	13
Do not use NOAC for patients undergoing ablation	**46.88%**	15
Total		32

EP Wire - Practice of use of NOAC therapies in Europe

Q23 Does your institution have the following blood tests available to measure the anticoagulant effect of the various NOACs

Answered: 32 Skipped: 13



Answer Choices	Responses	
aPTT	81.25%	26
PT	68.75%	22
Hemoclot (diluted thrombin time)	37.50%	12
Ecarin clotting time	21.88%	7
antiFactor Xa assay	43.75%	14
not sure	28.13%	9
Total Respondents: 32		

EP Wire - Practice of use of NOAC therapies in Europe

Q24 Does your institution have protocols in place to deal with emergency bleeding or urgent surgery when patients are taking the various NOACs

Answered: 32 Skipped: 13



Answer Choices	Responses	
Protocol for emergency bleeding	**12.50%**	4
Protocol for emergency surgery	**0%**	0
Protocols for both (a and b)	**25%**	8
No protocols	**62.50%**	20
Total		32

EP Wire - Practice of use of NOAC therapies in Europe

Q25 Does your institution have the following interventions to deal with emergency bleeding or urgent surgery

Answered: 32 Skipped: 13



Answer Choices	Responses	
Prothrombin complex concentrates	**84.38%**	27
Recombinant Factor VIIa	**59.38%**	19
FEIBA	**25%**	8
Haemodialysis	**90.63%**	29
Charcoal filteration	**40.63%**	13
Not available, and have to refer elsewhere	**6.25%**	2
Total Respondents: 32		

EP Wire - Practice of use of NOAC therapies in Europe

Q26 Does your institution /department have any preference list (1st line treatment) if anticoagulation therapy is indicated in your AF patients?

Answered: 32 Skipped: 13



Answer Choices	Responses	
Yes	**40.63%**	13
No	**59.38%**	19
Total		32

Q27 If yes to previous Q, please list the general priority recommendation: 1-4 (1 = highest priority, 4 = lowest priority)

Answered: 15 Skipped: 30







EP Wire - Practice of use of NOAC therapies in Europe



Rivaroxaban					
	1	2	3	4	Total
Drugs	7.69% 1	15.38% 2	69.23% 9	7.69% 1	13

Dabigatran					
	1	2	3	4	Total
Drugs	21.43% 3	71.43% 10	7.14% 1	0% 0	14

Apixaban					
	1	2	3	4	Total
Drugs	0% 0	8.33% 1	16.67% 2	75% 9	12

Warfarin					
	1	2	3	4	Total
Drugs	73.33% 11	6.67% 1	6.67% 1	13.33% 2	15

Q28 The NOAC have been studied in a broad spectrum of patient groups, with various rates of thromboemblic and bleedings events. Given the knowledge that the results of these studies have differed leading to diverse number of approved indications, have this influenced your choice of NOAC for an individual patient?

Answered: 32 Skipped: 13



Answer Choices	Responses	
Yes	84.38%	27
No	15.63%	5
Total		32

#	Any Comments	Date
1	Electrical cardioversion: dabigatran. Older and or iller patients: rivaroxaban	6/11/2013 11:46 AM
2	Dabigatran 150 mg preferred dose and generally preferred to rivaroxaban; dabigatran avoided in CAD/ACS patients Rivaroxaban preferred in patients with poor compliance to a drug that has to be taken BID Apixaban generally preferred to rivaroxaban	5/26/2013 6:44 PM
3	But only mildly.	5/23/2013 9:15 AM
4	But the only available NOAC in my country is Dabigatran.	5/21/2013 11:20 PM
5	Rivaroxaban to pateints with coronary artery disease and to those with difficult compliance Dabigatran not given to patients with coronary artery disease or reduced kidney function	5/21/2013 4:42 PM

EP Wire - Practice of use of NOAC therapies in Europe

Q29 In patients already on VKA, when would you swop to a NOAC

Answered: 32 Skipped: 13



Answer Choices	Responses	
Never	**0%**	0
When side effects on VKA, inability to attend for monitoring, poor time in therapeutic range	**100%**	32
Total		32